Autoantibodies to IA-2 and GAD65 in patients with type 2 diabetes mellitus of varied duration: Prevalence and correlation with clinical features

Endocrine Practice

Volumn 7, Issue 5, 2001, Pages 339-345

  Grasso, Y Z ^a   Reddy, S K ^a   Rosenfield, C R ^a   Hussein, W I ^a   Hoogwerf, B J ^a   Faiman, C ^a   Gupta, M K ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; AUTOANTIBODY; GLUTAMATE DECARBOXYLASE; INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; PROTEIN TYROSINE PHOSPHATASE; SULFONYLUREA; SULFUR 35; TROGLITAZONE;

ADULT; AGED; ARTICLE; BODY MASS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION FUNCTION; DIET THERAPY; DISEASE DURATION; DISEASE MANAGEMENT; FEMALE; HUMAN; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; ISOTOPE LABELING; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; NON INSULIN DEPENDENT DIABETES MELLITUS; PREDICTION; PREVALENCE; RADIOASSAY; STATISTICAL ANALYSIS;

EID: 0035442538     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.7.5.339     Document Type: Article

References (28)

1. Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA type
2. Factors influencing the magnitude, duration, and rate of fall of B-cell function in type 1 (insulin-dependent) diabetic children followed for two years from their clinical diagnosis
3. Evidence for different clinical subtypes of type 1 diabetes mellitus: A prospective study
4. Persistence of serum antibodies to a 64,000-Mr islet cell protein after onset of type I diabetes
5. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop
6. Prediction of type I diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2 autoantibodies
7. GADIA2-combi determination as first-line screening for improved prediction of type 1 diabetes in relatives
8. UKPDS 25: Autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes
9. GAD antibodies in NIDDM: Ten-year follow-up from the diagnosis
10. Autoantibodies to glutamic acid decarboxylase and phenotypic features associated with early insulin treatment in individuals with adult-onset diabetes mellitus
11. Type 1 diabetes in insulin-treated adult-onset diabetic subjects
12. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type
13. GAD 65 antibody but not ICA positivity in adult-onset diabetic patient is associated with early progression to clinical insulin dependency
14. Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies
15. Latent autoimmune diabetes mellitus in adults (LADA): The role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency
16. Antibodies to IA-2 and GAD65 in type 1 and type 2 diabetes: Isotype restriction and polyclonality
17. Detection of GAD65 antibodies in diabetes and other autoimmune diseases using a simple radioligand assay
18. Islet amyloid, increased A-cells, reduced B-cells and exocrine fibrosis: Quantitative changes in the pancreas in type 2 diabetes
19. Antibodies to the M(r) 65,000 isoform of glutamic acid decarboxylase are detected in non-insulin-dependent diabetes in Japanese
20. Antibodies to glutamic acid decarboxylase discriminate major types of diabetes mellitus
21. Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus
22. Islet cell clustering and peripheral blood mononuclear response to human islet antigens in antibody positive NIDDM patients
23. Antibodies to glutamic acid decarboxylase in Australian children with insulin-dependent diabetes mellitus and their first-degree relatives
24. Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: A population-based study
25. Subtype of insulin-dependent diabetes mellitus (IDDM) in Japan: Slowly progressive IDDM-the clinical characteristics and pathogenesis of the syndrome
26. The pathogenesis and prevention of diabetes in adults: Genes, autoimmunity, and demography
27. Islet cell antibodies identify latent type I diabetes in patients aged 35-75 years at diagnosis
28. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus